Quantcast

Genesis Biopharma Names Marvin S. Hausman M.D. as Chief Science Officer

March 7, 2011

LOS ANGELES, March 7, 2011 /PRNewswire/ — Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Marvin S. Hausman M.D. as Chief Science Officer. Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies.

“We are very fortunate to have Marvin Hausman join the team at Genesis Biopharma,” said Anthony J. Cataldo, President and Chief Executive Officer. “Dr. Hausman has an outstanding track record in identifying and developing breakthrough medical technologies, and in building companies. I believe his ability to form successful partnerships and strategic alliances will be an important asset as we grow the Company and create shareholder value.”

Dr. Hausman currently serves as Chairman of the Board and Chief Executive Officer of Total Nutraceutical Solutions, Inc. Previously he was the President, Chief Executive Officer, Acting Principal Accounting and Financial Officer and Chairman of the Board of OXIS International, Inc. until May 2008 when he resigned. Dr. Hausman was also a director and Chairman of the Board of Axonyx from 1997 until the merger of Axonyx into Torrey Pines Therapeutics in October 2006, and had served as President and Chief Executive Officer of Axonyx from 1997 until September 2003 and March 2005, respectively. Dr. Hausman was a co-founder of Medco Research Inc., a pharmaceutical biotechnology company specializing in adenosine products which was subsequently acquired by King Pharmaceuticals. He has also served as a director of Arbios Technologies from 2003 to 2005 and of Regent Assisted Living, Inc. from 1996 to 2001. Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at UCLA Medical Center. He received his medical degree from New York University School of Medicine in 1967 and is a Board Certified Urological Surgeon.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as “expect,” “potential,” “suggests,” “bodes,” “may,” “should,” “could” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.


Source: newswire



comments powered by Disqus